Intermediate-Term Outcomes of Permissive Cardiotoxicity in Patients With Breast Cancer Receiving Trastuzumab
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Three-Year Outcomes Following Permissive Cardiotoxicity in Patients on Trastuzumab
Oncologist 2023 Apr 24;[EPub Ahead of Print], S Zhou, F Cirne, J Chow, A Zereshkian, L Bordeleau, S Dhesy-Thind, PM Ellis, SD Mukherjee, N Aghel, DP LeongFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.